Prevention of hospital-acquired infection in adult, critically ill patients Infections and Infestations
Conditions
Interventions
Following consent, the intervention will start within 48 hours of critical care admission and continue for 10 days or until hospital discharge, whichever is sooner. Randomisation will be performed usi
Sponsors
Queen Mary University of London
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years and over 2. Patients requiring intubation and ventilation OR requiring two or more other organ systems support (Sequential Organ Failure Assessment [SOFA] score =2 in >2 domains) without requiring intubation and ventilation 3. Patients predicted to remain in the critical care unit for at least 72 hours as determined by the Intensive Care Consultant with clinical responsibility for patient care
Exclusion criteria
Exclusion criteria: 1. Patients requiring total parenteral nutrition at time of enrolment 2. Palliative care admission for end-of-life care or withdrawal of active therapy as determined by the Intensive Care Consultant with clinical responsibility for patient care 3. Neutropaenia (400 mg/dl on admission to the Adult Critical Care Unit) 11. Enrolment in any other study with an IMP or a study that may have a similar primary outcome 12. Therapeutic anti-coagulation therapy 13. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The maximum tolerable dose (MTD) of Omegaven, calculated after the completion of the dose escalation based on the dose-limiting toxicity, which is in turn based on a review of adverse events attributable to the IMP | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Contacts
Public ContactZudin Puthucheary
Outcome results
None listed